Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The microRNA Expression Signature of Lung Adenocarcinoma Harboring EGFR Mutations: Identification of Therapeutic Targets for EGFR-TKI Combination Therapy.

International journal of molecular sciences - 19 Jul 2026

Tokunaga Takuya, Tomioka Yuya, Takeda Aya Harada, Ishihara Yuka, Nagata Ayako, Kato Mayuko, Suetsugu Takayuki, Mizuno Keiko, Aoki Masaya, Ueda Kazuhiro, Seki Naohiko

Abstract excerpt

Approximately half of Japanese patients with lung adenocarcinoma (LUAD) have epi-dermal growth factor receptor (EGFR) gene mutations. Therefore, EGFR is the most critical therapeutic target in treating LUAD. This study's purpose is to explore novel therapeutic targets for LUAD and further improve EGFR inhibitor combination therapy. We created microRNA (miRNA) expression signatures from clinical specimens of LUAD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Benzimidazoles

Share to Cyclin-Dependent Kinase 4

Share to Cyclin-Dependent Kinase 6

Share to Piperazines

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 42511755
DOI: 10.3390/ijms27146412
PMCID: PMC13411351

Genes

EGFR
CDK4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The microRNA Expression Signature of Lung Adenocarcinoma Harboring EGFR Mutations: Identification of Therapeutic Targets for EGFR-TKI Combination Therapy.PMID 42511755Read ↗

MiRNA-625-3p as novel biomarker promotes cell proliferation and metastasis of lung adenocarcinoma by targeting KLF9Semantic proximity Read ↗

Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas.Semantic proximity Read ↗

miRNA-218/FANCI is associated with metastasis and poor prognosis in lung adenocarcinoma: a bioinformatics analysisSemantic proximity Read ↗

The Role of miRNA-377 as a Tumor Suppressor in Lung Cancer by Negative Regulation of Genes Belonging to ErbB Signaling PathwaySemantic proximity Read ↗

A novel diagnostic system to evaluate epidermal growth factor receptor impact as a prognostic and therapeutic indicator for lung adenocarcinoma.Semantic proximity Read ↗

E2F8 exerts cancer-promoting effects by transcriptionally activating RRM2 and E2F8 knockdown synergizes with WEE1 inhibition in suppressing lung adenocarcinomaSemantic proximity Read ↗

EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell linesSemantic proximity Read ↗

miRNA expression profiling of lung adenocarcinomas: correlation with mutational status.Semantic proximity Read ↗

MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.Semantic proximity Read ↗

Identification of Tumor Suppressive miR-144-5p Targets: FAM111B Expression Accelerates the Malignant Phenotypes of Lung Adenocarcinoma.Semantic proximity Read ↗

Downregulation of NEDD4L by EGFR Signaling Promotes the Development of Lung AdenocarcinomaSemantic proximity Read ↗

Promising therapeutic efficacy and safety of a novel integrin α6-targeting peptide-drug conjugate in lung adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.